Humacyte, Inc. (HUMA) stock closed up 1.29% and analysts anticipate positive earnings, ranking #2 buy.

From Nasdaq: 2025-06-18 18:00:00

Humacyte, Inc. (HUMA) closed at $2.36, up 1.29% from the previous day, outperforming the S&P 500. Analysts anticipate an EPS of -$0.15 in the upcoming release, a 44.44% increase from the previous year. The Zacks Consensus Estimates project earnings of -$0.18 per share and a revenue of $8.77 million for the full year, showing positive changes.

Recent adjustments to analyst estimates for Humacyte, Inc. reflect shifting business patterns. Positive estimate revisions indicate analyst optimism about the company’s profitability. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), shows that Humacyte, Inc. currently holds a Zacks Rank of #2 (Buy). The Medical – Biomedical and Genetics industry has a Zacks Industry Rank of 88, positioning it in the top 36% of all industries.

Zacks Investment Research has identified 5 stocks set to double, with previous recommendations soaring as high as +232%. These picks offer an opportunity to get in on the ground floor of potentially high-growth stocks. Follow stock-moving metrics and industry rankings on Zacks.com for more insights and recommendations.



Read more at Nasdaq: Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know